We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.4457 | -1.36% | 32.3243 | 32.32 | 32.33 | 32.44 | 32.18 | 32.35 | 2,242,576 | 20:20:32 |
From May 2023 to May 2024
By Adria Calatayud
Roche Holding said a late-stage trial evaluating its Elevidys drug in Duchenne muscular dystrophy didn't reach its primary goal of showing improvement in a measure of motor function.
The Swiss pharmaceutical giant said late Monday that it will further analyze data from the trial, which evaluated its Elevidys drug in boys aged 4-7 years with Duchenne muscular dystrophy who could walk.
After 52 weeks of treatment, patients showed an improvement of 2.6 points on their North Star Ambulatory Assessment, a measure of motor function, compared to 1.9 points in placebo-treated patients, the company said.
Roche said the trial showed positive efficacy outcomes on functional secondary goals such as time to rise from floor and 10-meter walk test.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 31, 2023 02:11 ET (06:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
